Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research note issued on Thursday,Benzinga reports. They currently have a $6.00 price objective on the stock.
Separately, HC Wainwright increased their price objective on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday.
View Our Latest Stock Analysis on OCGN
Ocugen Trading Up 2.2 %
Institutional Investors Weigh In On Ocugen
Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Ocugen during the 4th quarter worth about $32,000. Tower Research Capital LLC TRC increased its position in shares of Ocugen by 309.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock worth $32,000 after purchasing an additional 30,120 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Ocugen during the 4th quarter worth about $40,000. Two Sigma Securities LLC increased its position in shares of Ocugen by 92.9% during the 4th quarter. Two Sigma Securities LLC now owns 51,909 shares of the company’s stock worth $42,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management acquired a new stake in shares of Ocugen during the 4th quarter worth about $56,000. Institutional investors and hedge funds own 10.27% of the company’s stock.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Further Reading
- Five stocks we like better than Ocugen
- What Are Some of the Best Large-Cap Stocks to Buy?
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- How to Calculate Return on Investment (ROI)
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- EV Stocks and How to Profit from Them
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.